Claims for Patent: 5,302,400

Summary for Patent: 5,302,400

Title:	Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
Abstract:	Disclosed are gastric acid-resistant polymer-coated digestive enzymes/buffered-bile acid compositions, process for their preparations and methods of treating digestive disorders, impaired liver function, cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering said compositions to a mammal in need of such treatment.
Inventor(s):	Sipos; Tibor (Lebanon, NJ)
Assignee:	Digestive Care Inc. (Lebanon, NJ)
Application Number:	07/901,758
Patent Claims:	1. A process for preparing a digestive enzyme/buffered- bile acid composition for the treatment of digestive enzymes/ursodeoxycholate deficient mammals comprising the steps of: a) blending dry, powdery ingredients selected from the group consisting of (i) from about 65 to about 90% w/w of an enzyme selected from the group consisting of pancreatic proteases, lipases, nucleases and amylase; (ii) from about 0.3 to about 13% w/w of a buffered micronized bile acid, said buffer selected from the group consisting of sodium and potassium carbonate and bicarbonate, ammonium carbonate, tromethamine, ethanolamine, diethanolamine and triethanolamine, said buffer/bile acid forming a mixture of a 1 to 1 neutralization equivalent ratio; (iii) a buffering agent selected from the group consisting of from about 0.25 to about 5.0% w/w sodium carbonate (anhydrous), sodium bicarbonate, potassium carbonate, potassium bicarbonate and ammonium carbonate, and from about 0.25 to about 1.5% w/w, tromethamine, diethanolamine and triethanolamine; (iv) of from about 3.0 to about 19% w/w of an adhesive polymer selected from the group consisting of polyvinylpyrrolidone, cellulose acetate phthalate, and a 60:40 blend of hydroxypropylmethyl cellulose, and ethyl cellulose; (v) of from about 0.5 to about 16% w/w a disintegrant selected from the group consisting of starch, modified starches, microcrystalline cellulose and propylene glycol alginate; b) wetting said blended ingredients with a liquid to cause the blend to stick together, wherein said liquid is selected from the group consisting of: 1%-25% w/w ethanol/75%-99% w/w 2-propanol/0.2%-2.5% w/w water; 98%-99% w/w 2-propanol/0.2%-2.0% w/w water; 1%-25% w/w methanol/0.2%-2.5% w/w water/75%-98% w/w 2 propanol/1%-5% w/w ethylacetate; c) granulating or extruding the liquid-wetted blend through a 10 or 18 mesh standard sleve screen; d) converting the granules to a uniform diameter particle size; e) compacting the uniform particles to spherical particles; f) drying the spherical particles under drying conditions not exceeding 35.degree. C. and 40% relative humidity; g) separating the spherical particles if not of uniform size according to desired sizes using U.S. Standard sieve screens; h) coating the particles with from about 7.0 to about 15% of a gastric acid-resistant polymer that disintegrates under neutral or slightly basic conditions selected from the group consisting of hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, an aqueous enteric coating polymer dispersion and an acrylic based polymeric dispersion; and i) drying the polymer-coated spherical particles under drying conditions not exceeding 35.degree. C. and 40% relative humidity. 2. The process of claim 1 wherein said digestive enzyme is selected from the group consisting of Pancreatin, Pancrelipase, Trypsin, Chymotrypsin, Chymotrypsin B, Pancreatopeptidase, Carboxypeptidase A, Carboxypeptidase B, Glycerol Ester Hydrolase, Phospholipase A2, Sterol Ester Hydrolase, Ribonuclease, Deoxyribonuclease, .alpha.-Amylase, Papain, Chymopapain, Bromelain, Ficin, .beta.-Amylase, Cellulase and .beta.-Galactosidase. 3. The process of claim 1 wherein said composition is in the form of microspheres having a mesh size of about 10 to 80. 4. The process of claim 1 wherein said liquid for wetting the blended ingredient comprises from about 0.2% to about 2.5% moisture. 5. The process of claim 4 wherein said moisture content is from 0.2 to 1.5%. 6. The process of claim 5 wherein said moisture content is from 0.2 to 1.0%. 7. The digestive enzyme/buffered bile acid compositions for the treatment of digestive enzyme/ursodeoxycholic deficient mammals prepared by the process of claim 1. 8. A process for preparing a digestive enzyme/buffered-ursodeoxycholic acid composition for the treatment of digestive enzymes/ursodeoxycholic acid deficient mammals comprising the steps of: a) preparing a starting seed of the buffered-ursodeoxycholic acid comprising: micropulverizing the buffered-ursodeoxycholic acid in a centrifugal grinder or an impact pulverizer, blending the resultant micronized buffered-ursodeoxycholic acid with a disintegrant and a buffering agent; b) spraying said blend with a solution of the adhesive polymer until the blend agglomerates; c) granulating or extruding the liquid-wetted blend through a 10 or 18 mesh Standard Sleve screen; d) converting the granules to a uniform diameter particle size of 40 to 60 mesh; e) compacting the uniform particles to spherical particles; f) drying the spherical particles; g) separating the spherical particles if not of uniform size according to desired sizes using U.S. Standard sieve screens; h) using said 40 to 60 mesh particles as starting seeds for the preparation of larger microspheres; placing the 40-60 mesh starting seeds in a rotating coating pan, wetting the microspheres with the liquid/adhesive polymer-containing mixture followed by slowly dusting the buffered-UDCA/buffer/disintegrant composition over the tumbling and flowing buffered-UDCA seed until the desired particles sizes are obtained; i) coating the particles with a gastric acid-resistant polymer that dissolves under neutral or slightly basic conditions; and j) drying the polymer coated spherical particles. 9. The process of claim 8 wherein the particle size range of said starting seeds are from about 20 to about 60 mesh. 10. The process of claim 8 wherein said starting seed is selected from the group consisting of: sodium and potassium carbonate and bicarbonate, buffered-ursodeoxycholic acid; buffered-ethyl and propyl esters of ursodeoxycholic acid; sodium and potassium carbonate and bicarbonate blends of glycyl and tauroursodeoxycholic acid; buffered blends of N-methyl glycyl ursodeoxycholic acid and N-methyl tauroursodeoxycholic acid.

Details for Patent 5,302,400

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	November 10, 1982	5,302,400	2040-03-30
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	August 21, 1984	5,302,400	2040-03-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	December 09, 1996	5,302,400	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	April 30, 2009	5,302,400	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	June 10, 2011	5,302,400	2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	March 14, 2013	5,302,400	2040-03-30

International Patent Family for US Patent 5,302,400

Country	Patent Number	Estimated Expiration
Canada	2096004
Australia	4132993